The main problem of introducing the new intranasal flu vaccine is to choose the manufacturer, says drey Vasin, the director of the A. A. Smorodintsev Research Institute of Influenza.
“When a drug reaches late-stage clinical trials, a manufacturer must be identified. Production is likely a critical stage at this point, as there is currently no industrial partner with the capacity to manufacture this type of vaccine. The future of this vaccine will depend on that,” Vasin said at the XII OpenBio Russian Biotechnology Forum in the Koltsovo science town (quote from RIA Novosti).
The expert is confident in the potential of the nasal flu vaccine. “The development of this vaccine has been going on for a long time. Preclinical studies have been completed, and clinical studies are underway. I am sure that it will be effective,” said Andrey Vasin.